E-LIB Suche - Ergebnisse für: Kalakonda, N.

1

Five‐year efficacy and safety of tafasitamab in patients wi..:

Duell, J. ; Abrisqueta, P. ; Andre, M....
Hematological Oncology. 41 (2023) S2 - p. 437-439 , 2023

Link: https://doi.org/10.1002/..

2

CREATION OF ISOGENIC CELL LINE MODELS OF 17P DELETION TO ST..:

van Kampen, F. L. ; Glenn, M. ; Pettitt, A...
Hematological Oncology. 41 (2023) S2 - p. 798-799 , 2023

Link: https://doi.org/10.1002/..

3

P1187: END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOST..:

Gleeson, M. ; Arias, C. ; Cunningham, D....
HemaSphere. 6 (2022) - p. 1073-1074 , 2022

Link: https://doi.org/10.1097/..

4

Diffuse large B cell lymphoma (DLBCL) in patients older tha..:

Hounsome, L. ; Eyre, T. A. ; Ireland, R....
British Journal of Cancer. 126 (2021) 1 - p. 134-143 , 2021

Link: https://doi.org/10.1038/..

5

PCN325 Health Utility in Relapsed/Refractory Diffuse Large ..:

Casasnovas, R.O. ; Daniele, P. ; Tremblay, G....
Value in Health. 23 (2020) - p. S479-S480 , 2020

Link: https://doi.org/10.1016/..

6

BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐..:

Pettitt, A. ; Kalakonda, N. ; Cicconi, S....
Hematological Oncology. 37 (2019) S2 - p. 217-218 , 2019

Link: https://doi.org/10.1002/..

7

PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY O..:

Salles, G. ; Duell, J. ; González Barca, E....
Hematological Oncology. 37 (2019) S2 - p. 173-174 , 2019

Link: https://doi.org/10.1002/..

8

EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY:..:

Radford, J. ; Connors, J.M. ; Younes, A....
Hematological Oncology. 37 (2019) S2 - p. 290-291 , 2019

Link: https://doi.org/10.1002/..

9

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REF..:

Kalakonda, N. ; Cavallo, F. ; Follows, G....
Hematological Oncology. 37 (2019) S2 - p. 62-64 , 2019

Link: https://doi.org/10.1002/..

10

POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CEL..:

Till, K.J. ; Gallardo Zapata, J. ; Marks, T....
Hematological Oncology. 37 (2019) S2 - p. 511-512 , 2019

Link: https://doi.org/10.1002/..

11

NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESP..:

Pettitt, A.R. ; Barrington, S. ; Kalakonda, N....
Hematological Oncology. 37 (2019) S2 - p. 67-68 , 2019

Link: https://doi.org/10.1002/..

12

SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH ..:

Nowakowski, G. ; Willenbacher, W. ; Greil, R....
Hematological Oncology. 37 (2019) S2 - p. 132-134 , 2019

Link: https://doi.org/10.1002/..

13

THE ROLE OF 18F FDG‐PET/CT IN PERIPHERAL T‐CELL LYMPHOMA (P..:

Gleeson, M. ; Peckitt, C. ; Cunningham, D....
Hematological Oncology. 35 (2017) S2 - p. 244-245 , 2017

Link: https://doi.org/10.1002/..

14

EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EI..:

Pettitt, A.R. ; Kalakonda, N. ; Polydoros, F....
Hematological Oncology. 35 (2017) S2 - p. 88-89 , 2017

Link: https://doi.org/10.1002/..

15

PHASE II STUDY OF DURVALUMAB (ANTI–PD‐L1) COMBINED WITH EIT..:

Jaeger, U. ; Kalakonda, N. ; Everaus, H....
Hematological Oncology. 35 (2017) S2 - p. 419-420 , 2017

Link: https://doi.org/10.1002/..